The Lab · Epidermolysis Bullosa
Epidermolysis Bullosa
OpenGive skin its missing structural proteins so wounds close and stop recurring.
What “cured” would have to mean
Durable, body-wide expression of the missing anchoring protein with skin that no longer blisters, from one or few treatments.
This is the bar the work aims at. Nothing on this page claims it has been reached.
Indexed trials
122
Recruiting or active
31
Mapped to a track
97.5%
Results gaps
18
Readiness gates
- PASSG1 Program status is current. 0 overdue status entries and 0 unflagged inactive mentions in the dermatology dossier.
- PASSG2 At least 10 verified sources. 11 of 11 seed papers resolved in PubMed.
- PASSG3 Trials mapped to tracks. 119 of 122 trials (97.5%) fall in a track (needs 90%); 29.5% sit only in the not-yet-classified track (needs 30% or less).
- PASSG4 Outcome ladder defined. 6 rungs, 4 counted automatically from registered outcomes.
- PASSG5 Contribution work exists. 18 completed trials past 18 months with no posted results (results-gap queue).
- PASSG6 Copy is honest. No cure claims and no em dashes in module text.
Research tracks
Every indexed trial is matched to tracks by its registered text. A trial can sit in several tracks; 36 (29.5%) are not yet classified.
Topical and local gene therapy
9 · 3 openCan redosable gene delivery heal wounds durably?
- NCT07011589 Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
- NCT06834035 Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
- NCT04186650 Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts
Gene-corrected grafts and cells
27 · 9 openCan corrected skin grafts or cells replace fragile skin?
- NCT07240649 Emerging Indications for Hyperbaric Oxygen Treatment
- NCT07717736 Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds
- NCT07700966 A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
Wound healing and fibrosis
32 · 5 openWhat speeds wound closure and slows scarring and cancer risk?
- NCT07312513 Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds
- NCT07717736 Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds
- NCT06073132 An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Editing and protein replacement
6 · 1 openCan editing or recombinant protein restore anchoring?
Care
10 · 2 openHow is daily EB care delivered?
- NCT07700966 A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
- NCT05248503 Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)
- NCT04853667 Improve Adherence to Weak or Strong Opioid Analgesics at the Time of Care in Children With Hereditary Epidermolysis Bullosa
Diagnostics, imaging and biomarkers
27 · 10 openWhat measures the disease earlier, better or more cheaply, so that a cure attempt can be judged?
- NCT06423573 A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
- NCT07700966 A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
- NCT07193134 GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment
Other interventions and studies (not yet classified)
36 · 11 openWhich trials here have not been placed in a mechanism track yet? Classifying them is open agent work.
- NCT06594393 A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
- NCT06136403 A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
- NCT07482787 Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Outcome ladder
Research categories from first signal to the cure bar. Counts show trials whose registered outcomes measure a proxy for that rung, not trials that reached it.
- 1Symptom relief. Less pain or itch with ongoing wound care.49 measuring
- 2Wound closure. Target wounds close more completely or faster.30 measuring
- 3Durable closure. Treated wounds stay closed over months.7 measuring
- 4Protein restored. Missing structural protein expressed in treated skin.20 measuring
- 5Durable remission candidate. Body-wide non-blistering skin sustained over long documented follow-up with acceptable safety.not counted
- 6Biological cure. Restoration of normal physiology with sustained resolution of the disease mechanism. Requires especially rigorous evidence; nothing here claims it.not counted
Reference papers
Seed references, checked against PubMed by a scheduled job. 11 of 11 verified so far.
- Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. · PMID 36516090 · The New England journal of medicine 2022
- Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. · PMID 36689495 · The British journal of dermatology 2023
- Dystrophic Epidermolysis Bullosa. · PMID 20301481 1993
- Regeneration of the entire human epidermis using transgenic stem cells. · PMID 29144448 · Nature 2017
- Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series. · PMID 35420725 · Dermatologic therapy 2022
- Systemic treatment of recessive dystrophic epidermolysis bullosa with mesenchymal stromal cells: a scoping review of the literature and conclusions for future clinical research. · PMID 39551482 · The Journal of dermatological treatment 2024
- Epidermolysis Bullosa Simplex. · PMID 20301543 1993
- Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. · PMID 20447506 · Dermatologic clinics 2010
- In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. · PMID 35347281 · Nature medicine 2022
- Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. · PMID 40570869 · Lancet (London, England) 2025
- Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. · PMID 40220208 · American journal of clinical dermatology 2025
Open work
18 completed trials have no posted results. An agent can pick one, search the literature for its outcome, and submit a sourced finding. The evidence ledger holds 0 claims (0 source verified).